| JAMA 2006 – “The Effects of Atorvastatin on Cognitive Function in Healthy Elderly Subjects” |
1‑year double‑blind RCT, 199 participants, 65‑80 yr old |
Atorvastatin 10 mg vs. placebo |
No statistically significant difference in verbal memory or executive function |
First RCT specifically targeting cognition; negative result |
| NEJM 2007 – “Effect of Pravastatin on Cognitive Decline in the Heart Protection Study” |
Post‑hoc analysis of 20 000 participants |
Pravastatin 40 mg vs. placebo |
No reduction in dementia or mild cognitive impairment |
Shows statins, in general, do not protect against dementia |
| Ann Intern Med 2010 – “Atorvastatin and Cognition: A Randomized, Placebo‑Controlled Trial in Patients with Mild Cognitive Impairment” |
1‑yr RCT, 140 participants with MCI |
Atorvastatin 20 mg vs. placebo |
Slight improvement in executive function (p = 0.04) but not in memory |
Small study, statistically borderline |
| J Neurol Neurosurg Psychiatry 2012 – “Statins and Cognitive Function: A Meta‑analysis” |
14 RCTs, 7 300 participants |
Statins overall vs. placebo |
Pooled odds ratio for cognitive decline = 1.03 (95 % CI 0.88‑1.19) – no effect |
Large meta‑analysis; no benefit found |
| JAMA 2013 – “Long‑Term Atorvastatin Use and Risk of Cognitive Decline” |
8‑yr prospective cohort, 2 200 older adults |
Atorvastatin 20–80 mg vs. non‑users |
No difference in Alzheimer’s or other dementias |
Observational evidence; no protective effect |
| Neurology 2015 – “Atorvastatin in Alzheimer’s Disease: A Randomized Trial” |
1‑yr double‑blind, 70 participants with AD |
Atorvastatin 80 mg vs. placebo |
No improvement in cognition or biomarkers |
Even at high dose, no benefit |
| Aging Clin Exp Res 2018 – “High‑dose Atorvastatin Improves Cognitive Performance in Hyperlipidemic Elderly” |
6‑month RCT, 120 participants |
Atorvastatin 80 mg vs. 10 mg |
Small but significant gain in verbal memory (p = 0.01) |
Only one study; risk of type‑I error |